摘要
目的:观察平艾合剂Ⅰ号方治疗艾滋病的疗效。方法:将107例患者分为单服平艾合剂Ⅰ号方(太芪培元颗粒)组与平艾合剂Ⅰ号方合用西药(齐多夫定300 mg、拉米夫定150 mg、奈韦拉平200 mg,每日两次)组,即中医组与中西医组。结果:经6个月治疗后,中医组患者中医证候积分、卡洛夫斯基积分、CD4+T淋巴细胞计数改善程度较中西医组明显,且差异有统计学意义。结论:平艾合剂Ⅰ号方有改善艾滋病患者症状,提高免疫力和生存质量的作用。
This study was aimed to observe the clinical effect of Ping-Ai Granules I in the treatment of HIV/ AIDS. A total of 107 AIDS cases were divided into Ping-Ai Granules I group and Ping-Ai Granules I united with HAART group. The results showed that there was significant difference between Ping-Ai Granules I group and Ping-Ai Granules I united with HAART group in aspects of symptoms, physical signs, Karnovsky Score and changes symptom of CD4＋ T lymphocyte. It was concluded that Ping-Ai Granules I had the function of improving patient＇s and increasing patient＇s immunity and living quality.
出处
《世界科学技术-中医药现代化》
北大核心
2013年第5期877-880,共4页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
基金
新疆维吾尔自治区科技厅科研机构创新发展专项(2013008):新疆艾滋病防治体系内中医药推广应用与研究,负责人:马建萍
科学技术部国家“十二五”重大科技专项(2012ZX10005010-001):中医药防治重大传染病临床科研基地与技术平台建设--中医药防治艾滋病临床科研基地建设,总课题负责人:张永利,子课题负责人:李兴旺
